Novel sialidase inhibitors suppress mumps virus replication and infection
Glycobiology · 2024
DOI: 10.1093/glycob/cwae059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Glycobiology, 2024. Verfasst von Tadanobu Takahashi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka 422-8526, Japan. Hauptthemen laut MEDLINE: Mumps virus, Virus Replication, Neuraminidase, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
The prevalent human pathogen, mumps virus (MuV; orthorubulavirus parotitidis) causes various complications and serious sequelae, such as meningitis, encephalitis, deafness, and impaired fertility. Direct-acting antivirals (DAAs) targeting MuV which can prevent mumps and mumps-associated complications and sequelae are yet to be developed. Paramyxoviridae family members, such as MuV, possess viral surface hemagglutinin-neuraminidase (HN) protein with sialidase activity which facilitates efficient viral replication. Therefore, to develop DAAs targeting MuV we synthesized MuV sialidase inhibitors. It is proposed that the viral HN has a single functional site for N-acetylneuraminic acid (Neu5Ac) binding and sialidase activity. Further, the known MuV sialidase inhibitor is an analog of Neu5Ac—2,3-didehydro-2-deoxy-N-acetylneuraminic acid (DANA)—which lacks potency. DANA derivatives with higher MuV sialidase inhibitory potency are lacking. The MuV-HN–Neu5Ac binding site has a hydrophobic cavity adjacent to the C4 position of Neu5Ac. Exploiting this, here, we synthesized DANA derivatives with increasing hydrophobicity at its C4 position and created 3 novel sialidase inhibitors (Compounds 1, 2, and 3) with higher specificity for MuV-HN than DANA; they inhibited MuV replication step to greater extent than DANA. Furthermore, they also inhibited hemagglutination and the MuV infection step. The insight—that these 3 novel DANA derivatives possess linear hydrocarbon groups at the C4-hydroxyl group of DANA—could help develop highly potent sialidase inhibitors with high specificity for MuV sialidase, which may function as direct-acting MuV-specific antivirals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, Shizuoka 422-8526, Japan.
- Department of Organic Chemistry, School of Pharmaceutical Sciences, Hiroshima International University, 5-1-1 Hirokoshinkai, Kure, Hiroshima 737-0112, Japan.
- Department of Functional Morphology, Faculty of Pharmacy, Juntendo University, 6-8-1 Hinode, Urayasu, Chiba 279-0013, Japan.
ORCID-Profile: Tadanobu Takahashi, Yuuki Kurebayashi, Tadamune Otsubo, Akira Minami, Hideyuki Takeuchi
Förderung
- JSPS KAKENHI
Zitieren
APA
Takahashi, T., Kurebayashi, Y., Otsubo, T., Ikeda, K., Konagaya, K., Suzuki, S., Yamazaki, M., Suzuki, K., Narimichi, Y., Minami, A., & Takeuchi, H. (2024). Novel sialidase inhibitors suppress mumps virus replication and infection. Glycobiology. https://doi.org/10.1093/glycob/cwae059
Vancouver
Takahashi T, Kurebayashi Y, Otsubo T, Ikeda K, Konagaya K, Suzuki S, et al. Novel sialidase inhibitors suppress mumps virus replication and infection. Glycobiology. 2024. doi:10.1093/glycob/cwae059
BibTeX
@article{Takahashi2024,
author = {Takahashi, Tadanobu and Kurebayashi, Yuuki and Otsubo, Tadamune and Ikeda, Kiyoshi and Konagaya, Kobun and Suzuki, Shunsuke and Yamazaki, Mika and Suzuki, Kenya and Narimichi, Yutaka and Minami, Akira and Takeuchi, Hideyuki},
title = {Novel sialidase inhibitors suppress mumps virus replication and infection},
journal = {Glycobiology},
year = {2024},
doi = {10.1093/glycob/cwae059}
}
EUVIMED